Loading...
Please wait, while we are loading the content...
Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
| Content Provider | Europe PMC |
|---|---|
| Author | Solimani, Farzan Meier, Katharina Ghoreschi, Kamran |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8250126&blobtype=pdf |
| Page Count | 5 |
| ISSN | 00142980 |
| Journal | European Journal of Immunology [Eur J Immunol] |
| Volume Number | 51 |
| DOI | 10.1002/eji.202149173 |
| PubMed Central reference number | PMC8250126 |
| Issue Number | 5 |
| PubMed reference number | 33675065 |
| e-ISSN | 15214141 |
| Language | English |
| Publisher | John Wiley and Sons Inc. |
| Publisher Date | 2021-03-22 |
| Publisher Place | Hoboken |
| Access Restriction | Open |
| Rights License | This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2021 The Authors. European Journal of Immunology published by Wiley‐VCH GmbH |
| Subject Keyword | Janus kinase JAK inhibitors SARS‐CoV‐2 severe COVID‐19 cytokine storm |
| Content Type | Text |
| Resource Type | Article |
| Subject | Immunology and Allergy Immunology |